Zura Bio (Nasdaq: “ZURA”), a San Diego, CA-based multi-asset clinical-stage biotechnology company, raised approximately $80M in funding.
The round was led by Deep Track Capital, Great Point Partners, Suvretta Capital, and a life sciences-focused investment fund, alongside additional new and existing investors.
The company intends to use the funds to initiate a Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).
Led by CEO Dr. Someit Sidhu, Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders.
Zura Bio has approximately $120 million in cash and cash equivalents, which it believes will be sufficient to fund its planned operating expenses and capital expenditure requirements through 2026.
FinSMEs
06/06/2023